Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at Cantor's 2026 Global Healthcare Conference, scheduled for September 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on September 10 from 3:55 to 4:25 p.m. ET. A live webcast and replay will be available through the Investors section of the Tonix website, providing an opportunity for investors and analysts to gain insights into the company's strategic direction and pipeline progress.
This participation comes at a pivotal time for Tonix as it seeks to capitalize on the recent approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. The presentation at this major healthcare conference is likely to draw attention to Tonix's efforts to maximize the science behind TONMYA through Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder. If successful, these trials could expand the label of TONMYA, addressing significant unmet needs and potentially reshaping the therapeutic landscape for these psychiatric conditions.
Beyond its CNS portfolio, Tonix is advancing a pipeline of immunology programs, including TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company also has TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. These programs reflect Tonix's commitment to addressing high unmet medical needs across multiple therapeutic areas. The conference platform will allow Tonix to highlight the breadth of its research and development efforts, potentially attracting partnerships or investment to accelerate these initiatives.
Tonix's participation in the Cantor conference is important because it signals the company's proactive engagement with the investment community to communicate its progress and future prospects. The timing is critical, as the company is navigating the commercial launch of TONMYA and the advancement of its pipeline. The ability to articulate its strategy and data at a prominent investor conference could influence market perception and support the company's valuation. Moreover, the live webcast ensures transparency, allowing a broader audience to assess Tonix's potential.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's product development candidates are investigational new drugs or biologics, and their efficacy and safety have not been established. For the latest news and updates on TNXP, investors can visit the company's newsroom at https://nnw.fm/TNXP. The full press release is available at https://nnw.fm/hajiz.
